key: cord-0900501-e5fh7r7a
authors: Bahloul, Mabrouk; Ketata, Wajdi; Lahyeni, Dorra; Mayoufi, Houda; Kotti, Amina; Smaoui, Fatma; Kallel, Nessrine; Daoud, Emna; Bouaziz, Mounir; Kammoun, Samy
title: Pulmonary Capillary Leak Syndrome following COVID‐19 Virus Infection
date: 2020-06-10
journal: J Med Virol
DOI: 10.1002/jmv.26152
sha: e1e016b658e7ae3a0f6abf3b8f42ddc5589b95ac
doc_id: 900501
cord_uid: e5fh7r7a

Pulmonary capillary leak syndrome secondary to influenza SARS‐CoV‐2virus infection was not previously reported. We report 2 cases. The diagnosis of non‐cardiogenic pulmonary edema due to pulmonary capillary leak syndrome SARS‐CoV‐2 virus infection was obtained by a medical committee of 6 physicians. The diagnosis of COVID‐19 infection is confirmed by reverse transcription polymerase chain reaction (RT‐PCR) test. Moreover, in this specific endemic situation, and according to the British Society of Thoracic Imaging expert reference group update, we took account of chest CT‐Scan results in the early detection of COVID‐19 pneumonia. Our 2 patients with a confirmed influenza SARS‐CoV‐2virus infection had respiratory distress with lung crackles on auscultation of one or both lungs and with alveolar pulmonary edema on the chest CT‐Scan. The cardiogenic nature of pulmonary edema was ruled out in both cases by a transthoracic echocardiography showing normal systolic and diastolic functions. Our patients were treated by oxygen via face mask in one case and mechanical ventilation as supportive treatment in the other patient. Hydroxychloroquine (600mg/day), Azithromycine, steroids (dexamethasone 20mg/day), vitamin C (3g/day), Zinc, diuretics and Enoxaparine were equally used for the two patients. Evolution was marked by a good outcome in both of them. In summary, acute respiratory failure is a rare but major complication of COVID‐19 virus infection. It is due to pulmonary capillary leak syndrome. Treatment is based on a good oxygenation, intravenous corticosteroids, diuretics, Azithromycine, vitamin C, and other symptomatic treatments. This article is protected by copyright. All rights reserved.

Pulmonary capillary leak syndrome secondary to influenza SARS-CoV-2virus infection was not previously reported. We report 2 cases.

The diagnosis of non-cardiogenic pulmonary edema due to pulmonary 

regression of diffuse bilateral infiltrates (Fig. 1B) . She was discharged from ICU within 14 days after admission.

The second case is a 58-year-old man, without pathological antecedent, presented to the COVID-19 department with a history of 7 days of fever and anosmia. Six showed a showed a dispiriting of diffuse bilateral infiltrates (Fig. 1D) . He was discharged from ICU within 8 days after admission.

This article is protected by copyright. All rights reserved.

In our two patients the mode of contamination was not found, but due to the pandemic situation, COVID-19 virus is probably primarily transmitted between people through respiratory droplets and contact routes. Moreover, No other signs of capillary leak syndrome (edema over the leg, neither ascites) were observed in our two cases.

Acute respiratory failure due to infection with SARS-CoV-2, is due fundamentally In our practice, respiratory distress due to pulmonary capillary leak syndrome following COVID-19 infection is treated by conventional oxygen therapy. In summary, acute respiratory failure is a rare but major complication of COVID-19 virus infection. Although we report only 2 cases with limited information, we think that this complication is due in part to pulmonary capillary leak syndrome.

Treatment is based on a good oxygenation, intravenous corticosteroids, and other symptomatic treatments. Steroids were used to treat pulmonary capillary leak syndrome. 

Clinical features of covid-19

the continuing evolution of COVID-19 imaging pathways in the UK: a British Society of Thoracic Imaging expert reference group update

Histopathology and Genetic Susceptibility in COVID-19 Pneumonia

Pulmonary Capillary Leak Syndrome After Influenza A (H1N1) Virus Infection

Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence